A comprehensive view of FujiFilm Diosynth Biotechnologies. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FUJIFILM Diosynth Biotechnologies expands manufacturing agreement with argenx for the production of the autoimmune disease drug efgartigimod; the deal builds upon a previous agreement announced in October 2022

Fujifilm Diosynth Biotechnologies names Richard McAvoy as CFO effective April 1; McAvoy most recently served as VP of business support and site head for Fujifilm's US$2.0B large-scale cell culture manufacturing facility in Holly Springs, North Carolina

FujiFilm Diosynth Biotechnologies enters a 10-year deal with Better Energy to source 40 GWh of renewable energy annually from 2025; the electricity will cover the total electricity consumption at FujiFilm's Hillerod, Denmark manufacturing site

FUJIFILM Diosynth Biotechnologies signs a 10-year agreement with Better Energy to source 40 GWh of renewable energy annually; deal expected to supply total electricity consumption at the company’s Hillerod, Denmark biopharmaceutical manufacturing site

FUJIFILM Diosynth Biotechnologies partners with SHL Medical to expand its autoinjector services; the partnership aims to streamline production, enhance efficiency, and increase manufacturing capacity to 30 million units per year starting from 2025

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count